Amgen Inc. (NASDAQ:AMGN) Position Raised by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 125,617 shares of the medical research company's stock after buying an additional 1,839 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Amgen were worth $39,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Eagle Bay Advisors LLC lifted its position in shares of Amgen by 20.2% in the 1st quarter. Eagle Bay Advisors LLC now owns 1,215 shares of the medical research company's stock worth $379,000 after purchasing an additional 204 shares during the period. BKM Wealth Management LLC lifted its position in shares of Amgen by 1.7% in the 1st quarter. BKM Wealth Management LLC now owns 7,135 shares of the medical research company's stock worth $2,223,000 after purchasing an additional 119 shares during the period. Atlantic Union Bankshares Corp lifted its position in shares of Amgen by 1.3% in the 1st quarter. Atlantic Union Bankshares Corp now owns 4,016 shares of the medical research company's stock worth $1,251,000 after purchasing an additional 52 shares during the period. Twin Capital Management Inc. lifted its position in shares of Amgen by 41.7% in the 1st quarter. Twin Capital Management Inc. now owns 20,017 shares of the medical research company's stock worth $6,236,000 after purchasing an additional 5,895 shares during the period. Finally, IFP Advisors Inc lifted its position in shares of Amgen by 13.3% in the 1st quarter. IFP Advisors Inc now owns 6,911 shares of the medical research company's stock worth $2,153,000 after purchasing an additional 809 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.69% of the company's stock.

Amgen Stock Up 0.8%

Amgen stock traded up $2.42 during trading on Wednesday, reaching $308.11. The stock had a trading volume of 577,290 shares, compared to its average volume of 2,833,913. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The business has a 50 day moving average price of $285.90 and a 200 day moving average price of $289.56. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. The stock has a market cap of $165.68 billion, a PE ratio of 28.07, a P/E/G ratio of 2.67 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.96 EPS. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent analyst reports. Citigroup boosted their price objective on shares of Amgen from $300.00 to $305.00 and gave the stock a "neutral" rating in a research note on Tuesday. Guggenheim started coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price target on the stock. Mizuho upped their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Wall Street Zen upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Finally, Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $307.27.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.